Health and Healthcare

Teva : TEVA

All Teva Articles

450 Articles

Paul Ausick | Feb 13, 2017 at 7:55 AM EST

How Rosy Is the Outlook for Teva Pharmaceutical?

Teva beat estimates on earnings and revenues for both the quarter and the fiscal year and its outlook for 2017…

Chris Lange | Feb 12, 2017 at 10:25 AM EST

Top 7 Earnings to Look For This Week

24/7 Wall St. has put together a preview of Cisco, Pepsico and some of the other most anticipated quarterly earnings…

Jon C. Ogg | Feb 10, 2017 at 9:10 AM EST

Top Analyst Upgrades and Downgrades: Ford, Intel, NVIDIA, Starbucks, Teva, Twitter, Wal-Mart and Many More

[cnxvideo id=”509257″ placement=”ros”]Stocks were indicated marginally higher on Friday morning on what seems to be a very light news day.…

Chris Lange | Feb 10, 2017 at 8:35 AM EST

Are Short Sellers Doubting Trump by Hiking Bets in Major Pharma?

It has yet to be seen how much headway Trump can actually make with heath care reforms, but so far…

Paul Ausick | Feb 8, 2017 at 4:08 PM EST

Gilead Sciences, Fitbit Plunge into Wednesday’s 52-Week Low Club

Gilead Sciences, Gale Biopharma, Teva, and Fitbit post new 52-week lows Wednesday.

Paul Ausick | Feb 7, 2017 at 4:09 PM EST

Teva, Kors Stagger into Tuesday’s 52-Week Low Club

Teva, Michael Kors, Sabre, and comScore all posted new 52-week lows Tuesday.

Chris Lange | Feb 7, 2017 at 12:40 PM EST

Is Teva’s CEO Departure Long Overdue?

Teva Pharmaceutical saw its shares tumble on Tuesday after the company announced a changing of the guard. This CEO departure…

Chris Lange | Jan 31, 2017 at 1:05 PM EST

Why Analysts Are Chasing Momenta Pharmaceuticals Even Higher

Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) saw its shares make a huge gain on Tuesday after the firm reported a key…

Jon C. Ogg | Jan 31, 2017 at 10:50 AM EST

2 Key Analysts Strongly Defend Teva After Copaxone Patent Ruling Loss

When pharmaceutical companies lose patent cases on the blockbuster drugs, it usually means that they are at risk of losing…

Jon C. Ogg | Jan 31, 2017 at 9:10 AM EST

Top Analyst Upgrades and Downgrades: BP, Fitbit, Randgold, SLM, Teva, T-Mobile, GoPro and Many More

The top analyst upgrades, downgrades and initiations seen on Tuesday include BP, Fitbit, Randgold Resources, SLM, Teva Pharmaceuticals, T-Mobile and…

Chris Lange | Jan 26, 2017 at 9:50 AM EST

Short Sellers Run for Cover From Major Pharma

The January 13 short interest data have been compared with the previous figures, and short interest moves in these selected…

Paul Ausick | Jan 23, 2017 at 4:04 PM EST

Teva, Gilead Sciences Tumble into Monday’s 52-Week Low Club

DryShips, Teva, Endo Pharma, and Gilead Sciences posted new 52-week lows Monday.

Chris Lange | Jan 12, 2017 at 10:50 AM EST

Major Pharma Short Interest Declines Ahead of Trump Comments

The short interest data have been released for the December 30 settlement date. Pharmaceutical companies usually are involved in a…

Paul Ausick | Jan 11, 2017 at 4:04 PM EST

Macy’s, Teva Join Wednesday’s 52-Week Low Club

Macy's, Teva, DryShips, Merrimack Pharma lead Wednesday's 52-week low club.

Trey Thoelcke | Dec 30, 2016 at 11:15 AM EST

3 Sleeper Biotechs That Could Bounce Back Strong in 2017

2016 was hard for biotech stocks, some more than others. These three present a buy low opportunity.

1 … 12 13 14 15 16 … 30

Teva : TEVA

All Teva Articles

How Rosy Is the Outlook for Teva Pharmaceutical?

Top 7 Earnings to Look For This Week

Top Analyst Upgrades and Downgrades: Ford, Intel, NVIDIA, Starbucks, Teva, Twitter, Wal-Mart and Many More

Are Short Sellers Doubting Trump by Hiking Bets in Major Pharma?

Gilead Sciences, Fitbit Plunge into Wednesday’s 52-Week Low Club

Teva, Kors Stagger into Tuesday’s 52-Week Low Club

Is Teva’s CEO Departure Long Overdue?

Why Analysts Are Chasing Momenta Pharmaceuticals Even Higher

2 Key Analysts Strongly Defend Teva After Copaxone Patent Ruling Loss

Top Analyst Upgrades and Downgrades: BP, Fitbit, Randgold, SLM, Teva, T-Mobile, GoPro and Many More

Short Sellers Run for Cover From Major Pharma

Teva, Gilead Sciences Tumble into Monday’s 52-Week Low Club

Major Pharma Short Interest Declines Ahead of Trump Comments

Macy’s, Teva Join Wednesday’s 52-Week Low Club

3 Sleeper Biotechs That Could Bounce Back Strong in 2017

Oil’s 5.7% Weekly Drop Opens the Door for Jets, Materials, and Infrastructure ETFs

The 401(k) Move For 60-Year-Olds That Saves Six Figures in Lifetime Taxes: SECURE 2.0’s Hidden Roth Advantage

How to Build $3,000 a Month in Dividend Income Before You Turn 50

Oil's 5.7% Weekly Drop Opens the Door for Jets, Materials, and Infrastructure ETFs

The 401(k) Move For 60-Year-Olds That Saves Six Figures in Lifetime Taxes: SECURE 2.0's Hidden Roth Advantage

Oil’s 5.7% Weekly Drop Opens the Door for Jets, Materials, and Infrastructure ETFs

The 401(k) Move For 60-Year-Olds That Saves Six Figures in Lifetime Taxes: SECURE 2.0’s Hidden Roth Advantage

Teva : TEVA

All Teva Articles

How Rosy Is the Outlook for Teva Pharmaceutical?

Top 7 Earnings to Look For This Week

Top Analyst Upgrades and Downgrades: Ford, Intel, NVIDIA, Starbucks, Teva, Twitter, Wal-Mart and Many More

Are Short Sellers Doubting Trump by Hiking Bets in Major Pharma?

Gilead Sciences, Fitbit Plunge into Wednesday’s 52-Week Low Club

Teva, Kors Stagger into Tuesday’s 52-Week Low Club

Is Teva’s CEO Departure Long Overdue?

Why Analysts Are Chasing Momenta Pharmaceuticals Even Higher

2 Key Analysts Strongly Defend Teva After Copaxone Patent Ruling Loss

Top Analyst Upgrades and Downgrades: BP, Fitbit, Randgold, SLM, Teva, T-Mobile, GoPro and Many More

Short Sellers Run for Cover From Major Pharma

Teva, Gilead Sciences Tumble into Monday’s 52-Week Low Club

Major Pharma Short Interest Declines Ahead of Trump Comments

Macy’s, Teva Join Wednesday’s 52-Week Low Club

3 Sleeper Biotechs That Could Bounce Back Strong in 2017

Oil’s 5.7% Weekly Drop Opens the Door for Jets, Materials, and Infrastructure ETFs

The 401(k) Move For 60-Year-Olds That Saves Six Figures in Lifetime Taxes: SECURE 2.0’s Hidden Roth Advantage

How to Build $3,000 a Month in Dividend Income Before You Turn 50

Featured Reads

Oil's 5.7% Weekly Drop Opens the Door for Jets, Materials, and Infrastructure ETFs

The 401(k) Move For 60-Year-Olds That Saves Six Figures in Lifetime Taxes: SECURE 2.0's Hidden Roth Advantage